Developer docs
API playgroundTry for free, no card

Search company profiles

MyDNA

Full company profile

uuid00034um

Namestring
MyDNA
Legal namestring
myDNA Life Australia Pty Ltd
Websiteurl
mydna.life
Company typeenum
Private
Founded yearint
2007
Descriptiontext

MyDNA is a Melbourne-headquartered direct-to-consumer pharmacogenomics (PGx) testing company that helps individuals understand how their genetic profile affects their response to prescription medications. Founded in 2010 and operating through myDNA Life Australia Pty Ltd in Australia and a related entity, Gene by Gene Ltd, in the United States, the company primarily serves individual consumers seeking to reduce trial-and-error prescribing and adverse drug reactions, with secondary channels through healthcare providers (doctors, pharmacists, psychiatrists) who receive and act on test results, pharmacy distribution partners, and private health insurers Bupa (via Blua) and Medibank.

The company's core products are the Multiple Category Medication Test ($198 AUD), covering 100+ medications across 17+ therapeutic areas, and the Mental Health Medication Test ($149 AUD), covering 30+ mental health medications. Tests are processed through MyDNA's NATA-accredited Melbourne laboratory for Australian samples and Gene by Gene's CLIA/CAP/AABB/COLA-accredited Texas laboratory for US samples. Results are not released until after a consultation with a nominated healthcare professional, a clinical-embedded delivery model that combines DTC convenience with medical oversight. MyDNA extends its offering with a Personalised Wellness Test, Clinical Exome Screening, and a mobile app (myDNA Unlocked). It maintains a scientific partner ecosystem that spans Illumina, ThermoFisher, BC Platforms, and a network of Australian pathology providers.

MyDNA operates a primarily transactional revenue model, with revenue sourced from one-time test kit purchases ($149-$198 AUD per test), healthcare provider consultations that gatekeep the release of results, and insurance rebates through Bupa and Medibank. The company claims 85,000+ registered users, supports a 15-business-day turnaround, and runs a lean team of 51-100 employees. Its go-to-market spans direct e-commerce, pharmacy distribution, healthcare professional referrals, and insurance-channel partnerships. Funding to date totals approximately AUD $15.5M across three disclosed rounds between 2013 and 2016.

Short descriptiontext

MyDNA is a Melbourne-based direct-to-consumer pharmacogenomics company that sells DNA test kits (priced at $149-$198 AUD) to individuals and healthcare professionals to optimize medication prescribing across mental health, pain, cardiovascular, and gastrointestinal conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth Yarra, Australia
HQ citystring
South Yarra
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacogenomics testing, DNA medication testing, precision health genomics, genetic wellness screening, clinical exome sequencing
Industry3 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Pharmacogenomic Genetic Testing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct-to-Consumer DNA Test Kit Sales
TypeOne Time License
Description

One-time purchase of pharmacogenomic DNA test kits sold directly to consumers through the company's e-commerce website. Two main products: Multiple Category Medication Test at $198 and Mental Health Medication Test at $149. Results delivered via app and through a nominated healthcare professional consultation.

mydna.life
2Healthcare Provider Integration Revenue
TypeProfessional Services
Description

Test results are delivered to and discussed with nominated healthcare professionals (doctors, pharmacists) who then provide prescribing recommendations to patients, creating a healthcare-embedded revenue pathway.

mydna.life
3Private Health Insurance Rebates
TypeTransaction Fee
Description

Bupa (through Blua) and Medibank members are eligible for rebates on pharmacogenomic testing, creating an insurance-reimbursed revenue component where applicable.

mydna.life
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Pricing details2 tiers
1Multiple Category Medication Test - covers 100+ medications across 19+ therapeutic categories
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$198 AUD per test. One-time purchase with lifetime relevance of results. Includes PDF report with results, analysis of current medications, and individualized prescribing recommendations.

mydna.life
2Mental Health Medication Test - covers 30+ commonly prescribed mental health medications
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$149 AUD per test. One-time purchase with lifetime relevance of results. Includes prescribing recommendations for doctor and actionable PDF report.

mydna.life
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1myDNA Unlocked
Description

Mobile application for DNA test activation and results access

mydna.life
+1 more record
Core offering1 text field

MyDNA sells direct-to-consumer pharmacogenomic (PGx) DNA test kits — primarily the Multiple Category Medication Test (AUD $198) covering 100+ medications and the Mental Health Medication Test (AUD $149) covering 30+ mental health medications. Customers self-administer a cheek swab at home, mail the sample to the company's NATA/CLIA/CAP/AABB-accredited laboratories (Melbourne for Australia, Gene by Gene in Texas for the US), and receive personalized prescribing recommendations via the myDNA Unlocked app after consultation with a nominated healthcare professional.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Only 50% of people respond to the first antidepressant they try, making pharmacogenomic testing potentially critical for mental health treatment optimization.
+1 more record
Product overview1 text field

MyDNA offers a suite of pharmacogenomics and wellness DNA testing products centered around two main test kits: the Multiple Category Medication Test (covering 100+ medications across 17+ therapeutic areas for $198) and the Mental Health Medication Test (covering 30+ mental health medications for $149). Both tests analyze how an individual's genetics affect their response to prescription medications and provide prescribing recommendations to healthcare professionals. The company also offers Personalised Wellness Tests (covering nutrition, fitness, sleep, and supplements) and Clinical Exome Screening for hereditary conditions. Results from medication tests require consultation with a healthcare professional, while wellness results are delivered directly to the user. The products are supported by a mobile app (myDNA Unlocked), an in-house CLIA-accredited laboratory (Gene by Gene), and partnerships with major pathology and scientific organizations.

Product and service5 records
1Multiple Category Medication Test
CategoryPharmacogenomic Medication Test
Description

At-home cheek-swab pharmacogenomics DNA test covering 100+ medications across pain management, gastroenterology, diabetes, high blood pressure, atrial fibrillation, seizure disorder, anxiety, ADHD/ADD, PTSD, schizophrenia, cardiovascular, dementia, Alzheimer's, high cholesterol, NSAIDs, clinical depression, bipolar disorder, OCD and psychotic disorder. Sold directly to consumers for AUD $198 with results delivered via the myDNA Unlocked app after a consultation with a nominated healthcare professional. Includes analysis of current medications and individualized prescribing recommendations in a lifetime-relevant PDF report.

2Mental Health Medication Test
CategoryPharmacogenomic Medication Test
Description

At-home cheek-swab pharmacogenomics test analyzing response to 30+ mental health medications including antidepressants, antipsychotics, ADHD medications and psychostimulants. Designed to reduce side effects and maximize medication effectiveness. Sold directly to consumers for AUD $149 with results delivered via the myDNA Unlocked app after a consultation with a nominated healthcare professional, including prescribing recommendations for the patient's doctor and an actionable PDF report.

3myDNA Unlocked Mobile App
CategoryMobile Application
Description

Mobile application available on Apple App Store and Google Play that lets users register their DNA test kit, access results, manage their account, and view personalized medication insights over time.

4Personalised Wellness Test
CategoryGenetic Wellness Test
Description

DNA-based personalised wellness test providing insights into nutrient needs, exercise response, sports injury risk, sleep, caffeine sensitivity, skin health and supplements, with results delivered directly to the user without the consultation requirement.

5Clinical Exome Screening Test
CategoryClinical Genetic Screening
Description

Genetic screening test providing insights into hereditary conditions including cancer, cardiac disease and neurological disorders, with results delivered to the customer's nominated healthcare professional.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or Integration
Description

Scientific partner network member. Illumina is a leading DNA sequencing and array technology provider. Listed as a scientific partner in MyDNA's partner ecosystem.

2Bupa (via Blua)
Strategic tierCoreTypeGTM or Marketing Partner
Description

Bupa, through its Blua health platform, supports Pharmacogenomic testing for their members by offering rebates. Bupa members can visit the Blua website to access personalized medicine testing with insurance reimbursement.

mydna.life
Strategic tierCoreTypeGTM or Marketing Partner
Description

Medibank members may be eligible for a rebate on pharmacogenetic testing. Medibank provides guidance on how to claim for pharmacogenetic testing through their claims process.

Strategic tierCoreTypeTechnology or Integration
Description

Gene by Gene Ltd is a US-based DNA laboratory located in Texas, USA, and is a related entity to myDNA Life Australia Pty Ltd. It serves as the company's in-house US laboratory providing genetic testing services. It holds CLIA, CAP, AABB, COLA accreditations and multiple state clinical laboratory permits and licenses.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Larger clinical genetic testing company with a CLIA-certified lab offering reproductive, oncology, and broader molecular tests. Comparable on lab operations, regulatory footprint, and clinical sales motion adjacent to PGx.

2Sema4
TypeDirect peer
Description

Clinical genomic and health intelligence company offering hereditary and pharmacogenomic panels through a CLIA-certified lab. Direct comparison on PGx testing, lab accreditation stack, and clinical-report-driven business model.

TypeDirect peer
Description

Clinical genetic testing company providing broad hereditary and PGx-related panels to clinicians. Operates a similar healthcare-professional-driven model to MyDNA's medication tests and competes for prescriber relationships and payer coverage.

TypeDirect peer
Description

Clinical genomic testing company offering exome, genome, and hereditary disease panels through CLIA/CAP labs. Comparable to MyDNA's Clinical Exome Screening and gene-by-gene laboratory infrastructure, with similar healthcare-professional-led delivery model.

TypeBroad incumbent
Description

The best-known direct-to-consumer genetic testing company, offering ancestry and health-related reports. While its scope is broader than MyDNA's pharmacogenomic focus, it competes for the same DTC genetic-testing consumer and has shaped category expectations around PGx and health-risk reporting.

TypeBroad incumbent
Description

Established clinical genetics company with hereditary cancer, pharmacogenomic, and mental health testing products. It overlaps directly with MyDNA's GeneSight-style pharmacogenomic offering and represents a much larger incumbent competing for prescriber-driven PGx demand.

TypeDirect peer
Description

Genetic testing company delivering hereditary cancer and pharmacogenomic insights directly to consumers and through employers/clinics. Closely comparable on the DTC + clinical-callback hybrid model MyDNA uses for its medication tests.

TypeRegional player
Description

One of Australia's largest pathology and diagnostic services companies, already listed as a scientific partner of MyDNA. Comparable as a regional pathology incumbent with the infrastructure to either partner with or compete against MyDNA in PGx.

9Ancestry
TypeBroad incumbent
Description

Large direct-to-consumer DNA testing company focused on ancestry and family history with growing health offerings. Competes for the same DTC genetic-testing consumer attention and channel, though without MyDNA's PGx clinical depth.

TypeRegional player
Description

Major Australian and international pathology operator running accredited diagnostic labs. Comparable as a regional incumbent in the Australian diagnostics market and a potential channel or competitor for MyDNA's pathology-integrated PGx offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MyDNA

Pharmacogenomic Genetic Testingmydna.life

MyDNA is a Melbourne-based direct-to-consumer pharmacogenomics company that sells DNA test kits (priced at $149-$198 AUD) to individuals and healthcare professionals to optimize medication prescribing across mental health, pain, cardiovascular, and gastrointestinal conditions.

What MyDNA does

MyDNA is a Melbourne-headquartered direct-to-consumer pharmacogenomics (PGx) testing company that helps individuals understand how their genetic profile affects their response to prescription medications. Founded in 2010 and operating through myDNA Life Australia Pty Ltd in Australia and a related entity, Gene by Gene Ltd, in the United States, the company primarily serves individual consumers seeking to reduce trial-and-error prescribing and adverse drug reactions, with secondary channels through healthcare providers (doctors, pharmacists, psychiatrists) who receive and act on test results, pharmacy distribution partners, and private health insurers Bupa (via Blua) and Medibank.

The company's core products are the Multiple Category Medication Test ($198 AUD), covering 100+ medications across 17+ therapeutic areas, and the Mental Health Medication Test ($149 AUD), covering 30+ mental health medications. Tests are processed through MyDNA's NATA-accredited Melbourne laboratory for Australian samples and Gene by Gene's CLIA/CAP/AABB/COLA-accredited Texas laboratory for US samples. Results are not released until after a consultation with a nominated healthcare professional, a clinical-embedded delivery model that combines DTC convenience with medical oversight. MyDNA extends its offering with a Personalised Wellness Test, Clinical Exome Screening, and a mobile app (myDNA Unlocked). It maintains a scientific partner ecosystem that spans Illumina, ThermoFisher, BC Platforms, and a network of Australian pathology providers.

MyDNA operates a primarily transactional revenue model, with revenue sourced from one-time test kit purchases ($149-$198 AUD per test), healthcare provider consultations that gatekeep the release of results, and insurance rebates through Bupa and Medibank. The company claims 85,000+ registered users, supports a 15-business-day turnaround, and runs a lean team of 51-100 employees. Its go-to-market spans direct e-commerce, pharmacy distribution, healthcare professional referrals, and insurance-channel partnerships. Funding to date totals approximately AUD $15.5M across three disclosed rounds between 2013 and 2016.

MyDNA firmographics

Firmographics
Name
MyDNA
Legal name
myDNA Life Australia Pty Ltd
Website
https://mydna.life
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
MyDNA is a Melbourne-based direct-to-consumer pharmacogenomics company that sells DNA test kits (priced at $149-$198 AUD) to individuals and healthcare professionals to optimize medication prescribing across mental health, pain, cardiovascular, and gastrointestinal conditions.
Ownership category
akta.pro rank

MyDNA industry classification

Industry
Product category
Pharmacogenomic Genetic Testing
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAIADAO
Home Diagnostic & Self-Test OTC Kits
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Pharmacogenomics testing
  • DNA medication testing
  • Precision health genomics
  • Genetic wellness screening
  • Clinical exome sequencing

Where MyDNA is headquartered

Location

Headquarters

HQ city
South Yarra
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

MyDNA business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Direct-to-Consumer DNA Test Kit Sales: One-time purchase of pharmacogenomic DNA test kits sold directly to consumers through the company's e-commerce website. Two main products: Multiple Category Medication Test at $198 and Mental Health Medication Test at $149. Results delivered via app and through a nominated healthcare professional consultation.
  2. Healthcare Provider Integration Revenue: Test results are delivered to and discussed with nominated healthcare professionals (doctors, pharmacists) who then provide prescribing recommendations to patients, creating a healthcare-embedded revenue pathway.
  3. Private Health Insurance Rebates: Bupa (through Blua) and Medibank members are eligible for rebates on pharmacogenomic testing, creating an insurance-reimbursed revenue component where applicable.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMultiple Category Medication Test - covers 100+ medications across 19+ therapeutic categories
Unit PricingPay-as-you-goMental Health Medication Test - covers 30+ commonly prescribed mental health medications

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

MyDNA product offering

Product offering

Core offering

MyDNA sells direct-to-consumer pharmacogenomic (PGx) DNA test kits — primarily the Multiple Category Medication Test (AUD $198) covering 100+ medications and the Mental Health Medication Test (AUD $149) covering 30+ mental health medications. Customers self-administer a cheek swab at home, mail the sample to the company's NATA/CLIA/CAP/AABB-accredited laboratories (Melbourne for Australia, Gene by Gene in Texas for the US), and receive personalized prescribing recommendations via the myDNA Unlocked app after consultation with a nominated healthcare professional.

Product overview

MyDNA offers a suite of pharmacogenomics and wellness DNA testing products centered around two main test kits: the Multiple Category Medication Test (covering 100+ medications across 17+ therapeutic areas for $198) and the Mental Health Medication Test (covering 30+ mental health medications for $149). Both tests analyze how an individual's genetics affect their response to prescription medications and provide prescribing recommendations to healthcare professionals. The company also offers Personalised Wellness Tests (covering nutrition, fitness, sleep, and supplements) and Clinical Exome Screening for hereditary conditions. Results from medication tests require consultation with a healthcare professional, while wellness results are delivered directly to the user. The products are supported by a mobile app (myDNA Unlocked), an in-house CLIA-accredited laboratory (Gene by Gene), and partnerships with major pathology and scientific organizations.

Differentiator

Problem solved

Functional benefit

Brands

  • myDNA Unlocked: Mobile application for DNA test activation and results access
  • Gene by Gene

Products and services

  • Multiple Category Medication Test At-home cheek-swab pharmacogenomics DNA test covering 100+ medications across pain management, gastroenterology, diabetes, high blood pressure, atrial fibrillation, seizure disorder, anxiety, ADHD/ADD, PTSD, schizophrenia, cardiovascular, dementia, Alzheimer's, high cholesterol, NSAIDs, clinical depression, bipolar disorder, OCD and psychotic disorder. Sold directly to consumers for AUD $198 with results delivered via the myDNA Unlocked app after a consultation with a nominated healthcare professional. Includes analysis of current medications and individualized prescribing recommendations in a lifetime-relevant PDF report.
  • Mental Health Medication Test At-home cheek-swab pharmacogenomics test analyzing response to 30+ mental health medications including antidepressants, antipsychotics, ADHD medications and psychostimulants. Designed to reduce side effects and maximize medication effectiveness. Sold directly to consumers for AUD $149 with results delivered via the myDNA Unlocked app after a consultation with a nominated healthcare professional, including prescribing recommendations for the patient's doctor and an actionable PDF report.
  • myDNA Unlocked Mobile App Mobile application available on Apple App Store and Google Play that lets users register their DNA test kit, access results, manage their account, and view personalized medication insights over time.
  • Personalised Wellness Test DNA-based personalised wellness test providing insights into nutrient needs, exercise response, sports injury risk, sleep, caffeine sensitivity, skin health and supplements, with results delivered directly to the user without the consultation requirement.
  • Clinical Exome Screening Test Genetic screening test providing insights into hereditary conditions including cancer, cardiac disease and neurological disorders, with results delivered to the customer's nominated healthcare professional.

Quantifiable outcome

  • Only 50% of people respond to the first antidepressant they try, making pharmacogenomic testing potentially critical for mental health treatment optimization.
  • +1 more outcomes

Companies that use MyDNA

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

MyDNA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MyDNA partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • IlluminacoreTechnology or IntegrationScientific partner network member. Illumina is a leading DNA sequencing and array technology provider. Listed as a scientific partner in MyDNA's partner ecosystem.
  • Bupa (via Blua)coreGTM or Marketing PartnerBupa, through its Blua health platform, supports Pharmacogenomic testing for their members by offering rebates. Bupa members can visit the Blua website to access personalized medicine testing with insurance reimbursement.
  • MedibankcoreGTM or Marketing PartnerMedibank members may be eligible for a rebate on pharmacogenetic testing. Medibank provides guidance on how to claim for pharmacogenetic testing through their claims process.
  • Gene by GenecoreTechnology or IntegrationGene by Gene Ltd is a US-based DNA laboratory located in Texas, USA, and is a related entity to myDNA Life Australia Pty Ltd. It serves as the company's in-house US laboratory providing genetic testing services. It holds CLIA, CAP, AABB, COLA accreditations and multiple state clinical laboratory permits and licenses.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

MyDNA competitors and assessment

Company assessment

Broad incumbents

  • Natera: Larger clinical genetic testing company with a CLIA-certified lab offering reproductive, oncology, and broader molecular tests. Comparable on lab operations, regulatory footprint, and clinical sales motion adjacent to PGx.
  • 23andMe: The best-known direct-to-consumer genetic testing company, offering ancestry and health-related reports. While its scope is broader than MyDNA's pharmacogenomic focus, it competes for the same DTC genetic-testing consumer and has shaped category expectations around PGx and health-risk reporting.
  • Myriad Genetics: Established clinical genetics company with hereditary cancer, pharmacogenomic, and mental health testing products. It overlaps directly with MyDNA's GeneSight-style pharmacogenomic offering and represents a much larger incumbent competing for prescriber-driven PGx demand.
  • Ancestry: Large direct-to-consumer DNA testing company focused on ancestry and family history with growing health offerings. Competes for the same DTC genetic-testing consumer attention and channel, though without MyDNA's PGx clinical depth.

Direct peers

  • Sema4: Clinical genomic and health intelligence company offering hereditary and pharmacogenomic panels through a CLIA-certified lab. Direct comparison on PGx testing, lab accreditation stack, and clinical-report-driven business model.
  • Invitae: Clinical genetic testing company providing broad hereditary and PGx-related panels to clinicians. Operates a similar healthcare-professional-driven model to MyDNA's medication tests and competes for prescriber relationships and payer coverage.
  • GeneDx: Clinical genomic testing company offering exome, genome, and hereditary disease panels through CLIA/CAP labs. Comparable to MyDNA's Clinical Exome Screening and gene-by-gene laboratory infrastructure, with similar healthcare-professional-led delivery model.
  • Color Genomics: Genetic testing company delivering hereditary cancer and pharmacogenomic insights directly to consumers and through employers/clinics. Closely comparable on the DTC + clinical-callback hybrid model MyDNA uses for its medication tests.

Regional players

  • Healius: One of Australia's largest pathology and diagnostic services companies, already listed as a scientific partner of MyDNA. Comparable as a regional pathology incumbent with the infrastructure to either partner with or compete against MyDNA in PGx.
  • Sonic Healthcare: Major Australian and international pathology operator running accredited diagnostic labs. Comparable as a regional incumbent in the Australian diagnostics market and a potential channel or competitor for MyDNA's pathology-integrated PGx offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

MyDNA social profiles

Digital presence

MyDNA compliance and trust

Trust signal

Compliance11 records

MyDNA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MyDNA leadership team

Management profile

Number of profiles

Profiles8 records

MyDNA funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MyDNA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MyDNA

What does MyDNA do?

MyDNA sells direct-to-consumer pharmacogenomic (PGx) DNA test kits — primarily the Multiple Category Medication Test (AUD $198) covering 100+ medications and the Mental Health Medication Test (AUD $149) covering 30+ mental health medications. Customers self-administer a cheek swab at home, mail the sample to the company's NATA/CLIA/CAP/AABB-accredited laboratories (Melbourne for Australia, Gene by Gene in Texas for the US), and receive personalized prescribing recommendations via the myDNA Unlocked app after consultation with a nominated healthcare professional.

Is MyDNA a public or private company?

MyDNA is a private company. It is classified as unknown and is currently operating.

When was MyDNA founded?

MyDNA was founded in 2007. It employs 11 to 50 people.

Where is MyDNA based?

MyDNA is headquartered in South Yarra, Australia, in the Oceania region.

How does MyDNA make money?

Three revenue lines are on record. Direct-to-Consumer DNA Test Kit Sales are the primary driver. The others are healthcare Provider Integration Revenue and private Health Insurance Rebates.

Who are MyDNA's main competitors?

Broad incumbents on record are Natera, 23andMe, Myriad Genetics and Ancestry. Direct peers are Sema4, Invitae, GeneDx and Color Genomics. Regional players are Healius and Sonic Healthcare.

Does MyDNA have an API?

No public API is recorded for MyDNA.

What industry is MyDNA in?

MyDNA's product category is Pharmacogenomic Genetic Testing. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAIADAO, Home Diagnostic & Self-Test OTC Kits. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienmyDNA and Gene by Gene Expand Global Genomics Infrastructure Network with UK Laboratory LaunchmyDNA and Gene by Gene opened a new genomic laboratory in Glasgow, Scotland, joining existing labs in Houston and Melbourne. The three-continent network processes over 1.5 million genetic samples annually, supporting healthcare, pharma, research, and consumer genomics.Business Wire BlogDirect-to-Consumer Genetic Testing Market and Technology Research Report 2024-2029, Profiles of Major Players - Ancestry, 23andMe, MyHeritage, myDNA, Dante Labs, and Color Health - ResearchAndMarkets.ResearchAndMarkets has published a market research report on the Direct-to-Consumer Genetic Testing sector, valuing the global market at USD 2.3 billion in 2024 with projections to reach USD 3.7 billion by 2029. The study profiles major industry players including Ancestry, 23andMe, MyHeritage, myDNA, Dante Labs, and Color Health, while analyzing market drivers such as dropping sequencing costs and challenges like privacy concerns. It provides a comprehensive overview of technological trends, regulatory frameworks across key regions, and competitive landscape dynamics.MydnaPersonalised Wellness & Health TestThe article discusses myDNA's Personalised Wellness Test, which provides insights into diet, nutrition, fitness, and lifestyle based on individual DNA. Currently priced at $99, the kit offers over 30 insights and aims to empower users to make healthier choices by analyzing their genetic data. The test emphasizes the importance of personalized health strategies informed by DNA analysis, with results accessible through the myDNA Unlocked app.PR NewswireGlobal Consumer DNA (Genetic) Testing Market Report 2021-2026: Raising Awareness About Novel Developments and Advancements in the DNA Testing MarketResearchAndMarkets.com published a market research report projecting the global consumer DNA testing market to grow from US$487.909 million in 2019 to US$1,095.5794 million by 2026, representing a compound annual growth rate of 12.25%. Key drivers include rising demand for direct-to-consumer genetic testing, genetic ancestry testing, and technological advancements, with major players such as Ancestry and 23andMe investing in innovative solutions. In January 2021, Australian genomics company myDNA announced a merger with FamilyTreeDNA and its parent company Gene By Gene to enhance scientific foundations for personalized insights.InsideprecisionmedicinemyDNA Merges with Gene by Gene, Uniting Personalized Genetics PioneersAustralian genomics company myDNA has merged with U.S. consumer DNA test developer FamilyTreeDNA and its parent Gene by Gene, with financial terms undisclosed. CEO Lior Rauchberger, M.D., will lead the combined company, while Gene by Gene co-founders Bennett Greenspan and Max Blankfeld join the board. The merged entity will offer genealogy, pharmacogenomics and nutrigenomic services.PR NewswirePharmacogenetic and Genealogy Pioneers Merge for Historic PartnershipAustralian genomics company myDNA has merged with U.S.-based consumer DNA testing company FamilyTreeDNA and its parent company Gene by Gene, with myDNA CEO Dr. Lior Rauchberger stepping into the role of CEO of the merged entities. The merger combines one of the leading global experts in genealogy, pharmacogenomic, and nutrigenomic services, with Gene by Gene co-founders Bennett Greenspan and Max Blankfeld joining the Board of Directors. Both companies cite shared beliefs about the potential of genetic information to provide actionable, personalized health and ancestry insights as the foundation for the partnership.PR NewswireAustralian Based myDNA™ Launches In United StatesmyDNA, an Australian wellness DNA company founded in 2007, has launched its Wellness & Nutrition and Vitamins DNA test kits in the United States market. The company offers personalized genetic testing products priced at $99 for Nutrition & Fitness and $89 for Vitamins, with results delivered via secure online portal within two weeks. myDNA has appointed celebrity trainer Luke Milton as its U.S. brand ambassador to support the market entry.